Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-09-06 07:00 |
Rapport financier semestriel d'Innate Pharma au 30 juin 2012
|
French | 179.7 KB | ||
| 2012-09-04 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) : Autorisation réglementa…
|
French | 41.5 KB | ||
| 2012-09-04 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) receives regulatory autho…
|
English | 41.3 KB | ||
| 2012-09-03 20:11 |
BILAN DE FIN DU CONTRAT DE LIQUIDITÉ CONCLU AVEC NATIXIS, CONCLUSION D’UN NOUVE…
|
French | 33.6 KB | ||
| 2012-09-03 20:11 |
SIGNING OF A LIQUIDITY CONTRACT WITH GILBERT DUPONT ENDING OF THE PREVIOUS LIQU…
|
English | 37.4 KB | ||
| 2012-07-09 07:15 |
Innate Pharma SA publie le nombre d’actions composant son capital social ainsi …
|
French | 29.8 KB | ||
| 2012-07-09 07:15 |
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) releases its total number…
|
English | 30.1 KB | ||
| 2012-07-02 07:15 |
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual Ge…
|
French | 30.1 KB | ||
| 2012-07-02 07:15 |
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce que son Assemblé…
|
English | 30.2 KB | ||
| 2012-06-11 07:15 |
Innate Pharma SA(Euronext Paris : FR0010331421 – IPH) annonce la tenue de son a…
|
French | 39.2 KB | ||
| 2012-06-11 07:15 |
Innate Pharma (Euronext Paris: FR0010331421 – IPH) to hold its Annual General M…
|
English | 39.3 KB | ||
| 2012-05-21 07:15 |
“L’immunologie et l’immunité innée, clés du traitement contre le cancer” telle …
|
French | 189.7 KB | ||
| 2012-05-21 07:15 |
“Immunology and Innate Immunity are Keys to Cancer Treatment” Conclusions of th…
|
English | 155.3 KB | ||
| 2012-05-10 07:15 |
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d’af…
|
French | 30.6 KB | ||
| 2012-05-10 07:15 |
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its turnover for t…
|
English | 30.4 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
